Trexquant Investment LP Has $19.98 Million Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Trexquant Investment LP lifted its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 36.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 232,246 shares of the company's stock after purchasing an additional 62,267 shares during the quarter. Trexquant Investment LP's holdings in Novo Nordisk A/S were worth $19,978,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. May Hill Capital LLC acquired a new stake in Novo Nordisk A/S in the 4th quarter valued at $419,000. Headlands Technologies LLC acquired a new stake in shares of Novo Nordisk A/S in the 4th quarter valued at $893,000. Boston Family Office LLC grew its holdings in shares of Novo Nordisk A/S by 0.6% in the 4th quarter. Boston Family Office LLC now owns 44,804 shares of the company's stock worth $3,854,000 after purchasing an additional 280 shares during the last quarter. OLD Mission Capital LLC acquired a new stake in shares of Novo Nordisk A/S during the 4th quarter worth about $43,275,000. Finally, Mosaic Financial Group LLC increased its position in shares of Novo Nordisk A/S by 180.7% during the 4th quarter. Mosaic Financial Group LLC now owns 4,856 shares of the company's stock worth $418,000 after purchasing an additional 3,126 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company's stock.

Novo Nordisk A/S Trading Down 5.9 %

Shares of NVO stock traded down $3.97 on Friday, hitting $63.13. The stock had a trading volume of 5,670,876 shares, compared to its average volume of 8,336,041. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. Novo Nordisk A/S has a twelve month low of $62.87 and a twelve month high of $148.15. The company has a fifty day moving average price of $81.36 and a two-hundred day moving average price of $97.26. The firm has a market cap of $283.31 billion, a P/E ratio of 19.19, a PEG ratio of 0.90 and a beta of 0.61.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, topping analysts' consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. As a group, analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The company also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be given a $0.7874 dividend. This represents a yield of 1.2%. The ex-dividend date of this dividend is Monday, March 31st. This is a positive change from Novo Nordisk A/S's previous semi-annual dividend of $0.51. Novo Nordisk A/S's dividend payout ratio (DPR) is currently 47.72%.

Analyst Ratings Changes

NVO has been the subject of several recent analyst reports. Kepler Capital Markets raised shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Thursday, March 13th. StockNews.com downgraded Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a research report on Friday, March 21st. BMO Capital Markets lowered their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an "outperform" rating for the company in a research note on Monday, December 23rd. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a research report on Monday, January 6th. Finally, UBS Group upgraded shares of Novo Nordisk A/S from a "sell" rating to a "buy" rating in a research report on Wednesday, January 8th. Three research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Novo Nordisk A/S presently has an average rating of "Moderate Buy" and a consensus target price of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.